Clarification on assertions made about Valeant’s business Allergan has based most of their analysis on IMS’s U.S. prescription data, including products that we do not own, and missing many products, geographies, and - Fluorometholone - Document - PDFSEARCH.IO

First Page	Meta Content
	Clarification on assertions made about Valeant’s business Allergan has based most of their analysis on IMS’s U.S. prescription data, including products that we do not own, and missing many products, geographies, and Add to Reading List Document Date: 2014-06-23 17:17:25 Open Document File Size: 465,88 KB Share Result on Facebook City Dysport / / Company Allergan / Pershing Square Capital Management L.P. / Biovail / Bausch & Lomb / Nestle / Assertion Facts / IMS Health / HP / Valeant / / Country Venezuela / Saudi Arabia / Mexico / Poland / Indonesia / Turkey / Russia / United States / Brazil / Canada / Australia / China / India / / Currency USD / / Event M&A / FDA Phase / Reorganization / Earnings Guidance / / Facility Specialty pharmacy / / IndustryTerm pharmaceutical industry / pipeline products / pharmaceutical prices / pharmaceuticals / consumer products / healthcare provider societies / pharmaceutical products / devices/device / / Organization U.S. Securities and Exchange Commission / CSA / / Person Dan Wechsler / Rajiv De Silva / / Position physician / Governor / analyst / Private / / Product Alphagan P / Wellbutrin XL / Retin-A / Rx / Pred-G / FML Forte / Pred Mild / IDP-118 / / Technology RAM / / URL http / SocialTag Plastic surgery Valeant Pharmaceuticals Bimatoprost Botulinum toxin Biovail Bausch & Lomb Research and development Fluorometholone Medicine Allergan

Clarification on assertions made about Valeant’s business Allergan has based most of their analysis on IMS’s U.S. prescription data, including products that we do not own, and missing many products, geographies, and Add to Reading List